



# EVD SURVIVOR PROGRAM IN DRC

F Tshimanga Kazadi, L Fontana, A Legand and A Chaillon

2025-03-05



EVD survivor program



- This dataset include **1139 unique individuals**.
- Participants underwent a **mean of 17.94 visits (min=1, max=44)**.
- Participants were followed for a **mean duration of 2.14 years (min=0.03, max=4.52)**.

# POPULATION CHARACTERISTICS

Characteristic	N = 1,139
<b>Sex</b>	
Female	627 (55%)
Male	512 (45%)
<b>Age</b>	
29 (1, 81)	
<b>Age group</b>	
≤5 yrs	61 (5.4%)
5-15 yrs	135 (12%)
15-25 yrs	281 (25%)
25-45 yrs	457 (40%)
45-65 yrs	177 (16%)
>65 yrs	24 (2.1%)
<b>occupation</b>	
Agriculteur	315 (30%)
Autre	115 (11%)
Enfant	183 (18%)
Étudiant	45 (4.3%)
Femme au foyer	208 (20%)
Fonctionnaire d'Etat	14 (1.3%)
Minier	18 (1.7%)
Personne d'affaire	44 (4.2%)
Professeur/Universitaire	10 (1.0%)
Professionnel de santé	89 (8.5%)
<b>nombre de visites</b>	1.00 (1.00, 37.00)
<b>nombre de visites psychologiques</b>	1.00 (1.00, 18.00)


n (%); Median (Min, Max)

## Sex and Age distribution

## Number of participants over time


## Visits

## Duration of follow up




# COMORBIDITIES AND COMPLICATIONS

## COMORBIDITIES



## COMPLICATIONS



# CLINICAL EVALUATION

## TRENDS


labels	6 months	12 months	18 months	24 months	36 months	Average	Improvement
Sensation grattage	6.43	0.00	0.00	0.00	15.18	4.32	-136.08
Murmures vesiculaires	65.62	70.89	63.86	60.71	42.41	60.70	35.37
Troubles sensitifs	100.00	0.00	0.00	0.00	0.00	20.00	100
Troubles equilibre coordination mouvements	100.00	100.00	100.00	100.00	0.00	80.00	100
Troubles sommeil	100.00	100.00	100.00	100.00	100.00	100.00	
Trouble langage	100.00	0.00	0.00	0.00	0.00	20.00	100
Flou visuel	0.00	0.00	0.00	0.00	7.85	1.57	-Inf
Abdomen sensible	0.00	0.00	0.00	0.00	6.81	1.36	-Inf

Clinical evolution of signs with a minimum prevalence of 10 cases and a minimum frequency of 5%.

# CLINICAL EVALUATION AT BASELINE

Prevalence

Frequency




Baseline evaluation of signs with a minimum prevalence of 10 cases.

## CLINICAL PRESENTATION OVER TIME




## CLINICAL PRESENTATION WITHIN THE FIRST 9 MONTHS



Clinical signs with a minimum prevalence of 10 cases and a minimum frequency of 5%.

## CLINICAL PRESENTATION WITHIN THE FIRST 3 YEARS



Clinical signs with a minimum prevalence of 10 cases and a minimum frequency of 5%.

# PSYCHOLOGICAL EVALUATION


## WITHIN THE FIRST 3 MONTHS

Started before EVD

Currently

Since last visit

Worsening since last visit




At 6 months

At 12 months

At 24 months

At 36 months

## Psychological evaluation at 6 months




## DAY BY DAY PREVALENCE TRENDS

Prevalence

Number of individuals

Prevalence of clinical symptoms  
(months from ECT exit)




## DISEASE BURDEN

# DISEASE BURDEN

At 12 months

At 24 months

At 36 months





# THANK YOU

Any questions or suggestions? Contact us: [Anaïs Legand](#) and [Antoine Chaillon](#)